Less than a tenth of patients who could benefit from obesity jabs like Wegovy are able to get them, states the World Health Organization as it releases its inaugural advice on the medications.
Considering in excess of 1,000,000,000 individuals worldwide currently obese, it is urging increased and just availability to GLP-1 medication.
Per projections, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken.
"Our latest guidelines recognises that excess weight is a chronic disease that can be treated with holistic and continuous care," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are significant obstacles to universal access to the jabs that can aid individuals in losing significant body mass, explains the body.
Skinny Jab Shortage
Even in the present best projected scenario, the manufacturing of such drugs might only reach about 100 million people – under 10% of those who need them, per the health organization.
The guideline urges governments and firms to widen access, via approaches such as licensing agreements.
Exclusive production rights on the active ingredient – the core ingredient of the drug Wegovy – is set to lapse in several countries in 2026.
The Way Weight-Loss Jabs Work
These medications imitate a body's own hormone to slow digestion, reduce hunger and boost satiety so people reduce food intake.
People commonly begin shedding pounds within a few weeks of starting on the weekly injections.
Research indicates patients may see weight return within a year of halting the treatment, as their normal appetite return.
Being above a healthy weight raises your risk for contracting diseases, like type 2 diabetes, heart disease, stroke, and specific cancers.
Excess weight impacts people in countries worldwide and was responsible for over three and a half million fatalities worldwide in 2024, per the health agency.
